Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TSE:3159
TSE:3159Specialty Retail

Maruzen CHI HoldingsLtd (TSE:3159) Profit Squeeze Deepens As Margins Slip to 1.8%

Maruzen CHI HoldingsLtd closed at ¥400 on Friday after a soft week and a flat month. Yet the real story sits in profitability. Q2 2027 net income of ¥247 million on revenue of ¥41,363 million keeps the lights on, but the squeeze on earnings power is now the central issue for this retailer. Over the last year the net profit margin has slipped to 1.8% from 2.7%. Short term traders may shrug at a muted price move, while long term holders have to ask how much pressure on that thin margin is...
NasdaqGM:SUPN
NasdaqGM:SUPNPharmaceuticals

Supernus Pharmaceuticals (SUPN) Just Drew Fresh Attention, What Is The Market Weighing?

Conference appearances put Supernus Pharmaceuticals in focus Supernus Pharmaceuticals (SUPN) is set to brief investors at two healthcare conferences on 9 and 10 September 2026, giving the biopharma group a fresh platform to outline its central nervous system portfolio. Recent trading has been softer, with the share price down 11.69% over the past month and 15.83% year to date at US$41.64. However, a 3-year total shareholder return of 42.46% and 5-year total shareholder return of 52.64% point...
NYSE:TJX
NYSE:TJXSpecialty Retail

Is TJX Companies (TJX) Stock Too Expensive After A 92% Run?

TJX Companies stock has delivered a strong 92.4% gain over the past five years, yet the latest intrinsic value work suggests the current share price may sit above what its cash flows justify. With the market multiples looking roughly in line and a low broader value score, investors are left weighing whether the recent pullback has gone far enough to change that picture. A 92.4% return over five years highlights how well long term holders of TJX Companies have done. This raises the bar for...
NasdaqGS:PYPL
NasdaqGS:PYPLDiversified Financial

PayPal (PYPL) Stock Looks Like A Bargain On Earnings But Faces Weak Growth Doubts

PayPal Holdings is in an unusual spot, with the share price down about 80% over five years while broad valuation checks now flag the stock as looking cheap rather than expensive. The roughly 80% decline over five years points to a market that has sharply reset expectations for PayPal’s future earning power. New products like the PYUSDX stablecoin platform can support sentiment around long term growth, while ongoing layoffs and restructuring may keep investors focused on execution risk and on...
TSE:3921
TSE:3921Software

NEOJAPAN (TSE:3921) Stock Looks Cheap As Margins Hold Firm

NEOJAPAN’s stock closed at ¥1,576 on the day of the Q2 2027 release, leaving the software specialist trading on a trailing P/E of 11.8x that sits below both direct peers and the wider Japan software group. The headline from the quarter is profit resilience. Basic earnings per share of roughly ¥33 and net income around ¥459 million keep trailing net margin near 22%, which is high for a software developer focused on recurring corporate customers. Price action looks cautious, yet the earnings...
NYSE:EL
NYSE:ELPersonal Products

Estée Lauder Companies (EL) Leadership Reset Puts Its Valuation Narrative To The Test

Recent leadership changes at Estée Lauder Companies (EL) have put technology, digital commerce and luxury brands in sharper focus, giving investors fresh context for thinking about the stock after a period of mixed returns. The leadership reshuffle comes after a choppy stretch for Estée Lauder Companies, with a 1-month share price return of 10.77% and a 90-day gain of 8.30%, in contrast with a year-to-date decline of 9.03% and a 3-year total shareholder return that is down 34.09%. Compare...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

Cytokinetics (CYTK) Shares In Focus After New Phase 3 Aficamten Data

Cytokinetics (NasdaqGS:CYTK) released new, detailed Phase 3 trial results for aficamten in hypertrophic cardiomyopathy, including expanded efficacy data. The company reported additional safety outcomes for aficamten across both obstructive and non obstructive hypertrophic cardiomyopathy patient groups in the Phase 3 program. Management outlined plans to file a supplemental drug application for aficamten, providing more clarity on the intended regulatory pathway. The fresh Phase 3 aficamten...
NZSE:SUM
NZSE:SUMHealthcare

Summerset (NZSE:SUM) Stock Trades Below Fair Value After A 41% Slide

Summerset Group Holdings has delivered a share price that is down 40.9% over five years, while current valuation checks still flag the stock as screening cheap on several fronts. For investors, that gap between a weak track record on returns and an apparently attractive valuation is the core issue that needs unpacking. Over the past five years the share price has declined 40.9%, which signals that the market has been cautious on the business and its prospects. Future revenue growth and cash...
NasdaqGS:QRVO
NasdaqGS:QRVOSemiconductor

Qorvo (QRVO) Stock Could Be 33% Overvalued As Merger Review Nears Completion

Qorvo has delivered a strong run this year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiple checks point to the shares trading at a premium rather than offering clear value. The recent merger driven optimism around the proposed tie up with Skyworks Solutions adds extra attention to a stock that already screens as expensive on broad valuation tests. Year to date, Qorvo is up 35.2%, which puts recent gains front and center when assessing whether the current...
NasdaqGS:GOOGL
NasdaqGS:GOOGLInteractive Media and Services

Alphabet (GOOGL) Could Be 30% Below Fair Value On Mitti Labs Carbon Credit Deal

Alphabet (GOOGL) is back in the sustainability spotlight after climate tech firm Mitti Labs announced a five year deal to deliver 1 million high integrity carbon credits tied to rice farming in India. Alphabet’s share price has drifted lower over the past quarter, with a 90 day share price return of 5.89% in the red, even as news has been dominated by heavy AI infrastructure spending, Gemini product launches and large clean energy deals such as the new Finnish nuclear and geothermal...
NasdaqGS:GRAB
NasdaqGS:GRABTransportation

What Does Grab Holdings (GRAB) Want From A Singapore BNPL Deal?

Grab Holdings (NasdaqGS:GRAB) is in talks to acquire Singapore based buy now pay later provider Atome Financial. The potential deal would fold Atome's consumer credit and instalment payment services into Grab's existing financial services platform. Management is reportedly considering this transaction after previous buyouts that expanded Grab's digital payments and lending reach in Southeast Asia. The reported negotiations for Atome Financial are an important development to weigh alongside...
NasdaqGS:SLAB
NasdaqGS:SLABSemiconductor

Silicon Laboratories (SLAB) Opens Austin R And D Lab As Valuation Looks Fully Priced

Silicon Laboratories (SLAB) just cut the ribbon on a new R&D lab at its Austin headquarters, backed in part by a $23 million Texas Semiconductor Innovation Fund grant and focused on advanced wireless chip development. Against that backdrop, Silicon Laboratories has seen strong share price momentum over a longer stretch, with a year to date share price return of 67.01% and a 1 year total shareholder return of 64.70% that sits on top of an 81.00% total shareholder return over three years. Short...
NasdaqGS:WING
NasdaqGS:WINGHospitality

Wingstop (WING) Unveils Football Season Offers, Is It Still 43% Undervalued?

Wingstop (WING) just tied its stock story to football season by rolling out a limited-time Lemon Pepper Trio and a scarce Wing Pass that bundles weekly game day orders for Club Wingstop members. The latest football themed launch comes after a rough stretch for Wingstop shareholders, with the year to date share price return down 54.41% and the 1 year total shareholder return falling 55.63%. However, a 5.95% 1 day and 7.23% 7 day share price gain around the Lemon Pepper and Wing Pass news hints...
NYSE:CRM
NYSE:CRMSoftware

Did Earnings Beat Just Shift Salesforce's (CRM) Investment Narrative?

Salesforce recently reported stronger than expected quarterly results, with AI driven products like Agentforce and its data offerings showing significant adoption momentum and supporting raised full year guidance. The surge in AI usage across the Salesforce platform, including thousands of paid Agentforce deals and rising AI related activity, points to growing customer reliance on embedded automation rather than experimental pilots. Next, we will look at how Salesforce's stronger AI driven...
NYSE:RS
NYSE:RSMetals and Mining

Reliance (RS) Heads To Jefferies Conference Following Demand Led Fair Value Debate

Reliance (RS) moves into focus ahead of management’s upcoming appearance at the Jefferies Global Industrials Conference on 9 September 2026, which gives investors fresh context for the recent share performance. Over the past month, Reliance’s share price return is down 7.7%, and the 90-day share price return is also weaker. Yet the year-to-date share price return of 33.26% and 1-year total shareholder return of 37.63% show that longer term momentum is still intact. Scan how Reliance compares...
NasdaqGS:INTC
NasdaqGS:INTCSemiconductor

Intel (INTC) Unveils Hardware Backed Edge AI Encryption Solution

Intel (NasdaqGS: INTC) and Atsign announced a new hardware-accelerated, end-to-end encrypted Agent-to-Agent communication solution for autonomous edge AI systems. The two companies report that the approach removes long-standing encryption bottlenecks for autonomous edge AI agents by integrating Atsign’s security architecture with Intel hardware security features. Atsign has joined the Intel Industrial Builders partner program, expanding the group of third parties building secure AI offerings...
TSE:7777
TSE:7777Biotechs

3-D Matrix (TSE:7777) Stock Faces Margin Squeeze Despite Stronger Revenue

3-D Matrix walked into this earnings print with the stock up modestly over the past month, trading at ¥379 and on a trailing P/E that sat below both the wider Japan market and the Asian biotech pack. The headline today is not the share price. It is the sharp profit squeeze in Q1 2027, where basic EPS dropped to ¥2.36 on revenue of ¥3,225 million, a far cry from the recent quarterly peak. Traders who focus only on the low multiple may be underestimating how much this margin pressure is shaping...
CPSE:ZEAL
CPSE:ZEALBiotechs

Zealand Pharma (CPSE:ZEAL) And The Obesity Story Behind Its Undervalued Narrative

Why Zealand Pharma’s Latest Share Issuance Matters Zealand Pharma (CPSE:ZEAL) has inched its share capital higher after employees exercised warrants, creating 31,247 new shares that will list on Nasdaq Copenhagen once Danish Business Authority registration is complete. Recent trading tells a different story to the incremental share issuance. Zealand Pharma’s share price has fallen 15.5% over the past month and is down 39.5% year to date, while the 5 year total shareholder return of 37.7%...
NasdaqGM:FLY
NasdaqGM:FLYAerospace & Defense

Firefly Aerospace (FLY) Stock Looks Fully Priced Despite A 52% Fall

Firefly Aerospace has had a tough run over the past year, with a steep share price decline sitting awkwardly next to valuation checks that still flag the stock as expensive rather than a bargain. The share price has fallen 51.7% over the last 12 months, which puts Firefly Aerospace firmly in the penalty box for many investors. Fresh contracts such as the multi launch deal with SSC Space and radar work linked to the U.S. Space Force can support long term revenue hopes. However, execution risk...
NYSE:BEN
NYSE:BENCapital Markets

How Could Franklin Templeton (BEN) Korea Pick Shape Its Asia Pacific Growth?

Franklin Templeton (NYSE:BEN) has appointed Kim In-keun as President and CEO of Franklin Templeton Korea. The appointment gives Franklin Templeton a leader with extensive experience working with institutional and public-sector investors in Korea. Management is using this change to push further into Asia-Pacific distribution channels, particularly among large financial institutions. Kim In-keun’s appointment to lead Franklin Templeton Korea is only part of how the group is reshaping its...
NasdaqGM:FCEL
NasdaqGM:FCELElectrical

FuelCell Energy (FCEL) Is Back In Focus, What Is The Market Weighing?

FuelCell Energy (FCEL) is back in focus after a shareholder class action lawsuit was filed on September 11, 2026, following its fiscal third quarter results and a sharp share price drop. Despite the latest legal action and earnings release, FuelCell Energy’s recent share price moves tell a mixed story. The stock has a 7 day share price return of 6.3% but a 30 day share price return that is down 21.9%, even as the year to date share price return sits at 94.5%. Over a longer horizon the picture...
TSE:9163
TSE:9163Professional Services

Nareru Group (TSE:9163) Stock Faces Margin Pressure Despite Stronger Profit Growth

The stock entered this earnings day with a flat near-term record and a solid 90-day gain, yet the valuation gap quietly set the stage. Nareru Group changed the conversation with one factor that is hard to ignore. Profitability pressure eased in the quarter as net income reached ¥582 million and basic EPS was ¥66.48, while the trailing net profit margin over the last year remained at 7.9%. The market now has to decide whether that improving quarterly profit picture matters more than the recent...
NasdaqGS:HSIC
NasdaqGS:HSICHealthcare

Henry Schein (HSIC) Could Be 9% Undervalued On New Diagnostics Distribution Wins

Henry Schein (HSIC) just deepened its footprint in advanced diagnostics by taking on a new distribution role for Applied BioCode’s MDx-3000 platform and supporting DermaSensor’s expanded rollout of a handheld skin cancer detection device. These diagnostics partnerships come as Henry Schein’s share price trades at US$88.36, with a 90 day share price return of 8.75% and a year to date share price return of 15.02%. The 1 year total shareholder return of 28.04% suggests that recent momentum has...
NasdaqGS:CBRS
NasdaqGS:CBRSSemiconductor

Cerebras Systems (CBRS) Could Be 54% Below Fair Value Following Finland AI Campus Plan

Cerebras Systems (CBRS) has committed to a new AI data centre campus in Mikkeli, Finland, a multi-phase project with Compute Nordic Finland that targets up to 165 MW of high-density AI compute capacity. Recent trading tells a more cautious story. Cerebras Systems has a share price of $191.93, with a 7 day share price return down 8.63% and a 30 day move lower by 26.76%, even after a 0.31% gain in the last session. Scan beyond Cerebras Systems and compare this data centre push with other AI...